{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:12:47Z","timestamp":1785463967114,"version":"3.56.0"},"reference-count":53,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Oncol"],"DOI":"10.3892\/ijo.2018.4457","type":"journal-article","created":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T09:28:19Z","timestamp":1530091699000},"source":"Crossref","is-referenced-by-count":2,"title":["Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells"],"prefix":"10.3892","author":[{"given":"Federica","family":"Fratangelo","sequence":"first","affiliation":[{"name":"Istituto Nazionale Tumori -IRCCS- \u2018Fondazione G. Pascale\u2019, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Camerlingo","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori -IRCCS- \u2018Fondazione G. Pascale\u2019, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Vincenza","family":"Carriero","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori -IRCCS- \u2018Fondazione G. Pascale\u2019, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Pirozzi","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori -IRCCS- \u2018Fondazione G. Pascale\u2019, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Palmieri","sequence":"additional","affiliation":[{"name":"Unit of Cancer Genetics, Institute of Biomolecular Chemistry, National Research Council, 07100 Sassari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giusy","family":"Gentilcore","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori -IRCCS- \u2018Fondazione G. Pascale\u2019, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Ragone","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori -IRCCS- \u2018Fondazione G. Pascale\u2019, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Minopoli","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori -IRCCS- \u2018Fondazione G. Pascale\u2019, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Antonio","family":"Ascierto","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori -IRCCS- \u2018Fondazione G. Pascale\u2019, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Letizia","family":"Motti","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori -IRCCS- \u2018Fondazione G. Pascale\u2019, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2018,6,27]]},"reference":[{"key":"key20200713185040_b1-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1101\/gad.191999.112","article-title":"Melanoma: From mutations to medicine","volume":"26","author":"Tsao","year":"2012","journal-title":"Genes Dev"},{"key":"key20200713185040_b2-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Cancer Genome Atlas Network: Genomic classification of cutaneous melanoma","volume":"161","author":"Akbani","year":"2015","journal-title":"Cell"},{"key":"key20200713185040_b3-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"key20200713185040_b4-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.hoc.2009.04.001","article-title":"BRAF signaling and targeted therapies in melanoma","volume":"23","author":"Dhomen","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"key":"key20200713185040_b5-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/CCO.0b013e3282f5271c","article-title":"The MAPK pathway in melanoma","volume":"20","author":"Fecher","year":"2008","journal-title":"Curr Opin Oncol"},{"key":"key20200713185040_b6-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ccr.2004.09.022","article-title":"Guilty as charged: B-RAF is a human oncogene","volume":"6","author":"Garnett","year":"2004","journal-title":"Cancer Cell"},{"key":"key20200713185040_b7-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"key20200713185040_b8-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"key20200713185040_b9-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S0140-6736(13)60802-8","article-title":"Cutaneous melanoma","volume":"383","author":"Eggermont","year":"2014","journal-title":"Lancet"},{"key":"key20200713185040_b10-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3389\/fonc.2015.00183","article-title":"Multiple molecular pathways in melanomagenesis: Characterization of therapeutic targets","volume":"5","author":"Palmieri","year":"2015","journal-title":"Front Oncol"},{"key":"key20200713185040_b11-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/nature09627","article-title":"COT drives resistance to RAF inhibition through MAP kinase pathway reactivation","volume":"468","author":"Johannessen","year":"2010","journal-title":"Nature"},{"key":"key20200713185040_b12-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"key":"key20200713185040_b13-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nature10662","article-title":"RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)","volume":"480","author":"Poulikakos","year":"2011","journal-title":"Nature"},{"key":"key20200713185040_b14-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1158\/2159-8290.CD-12-0470","article-title":"A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition","volume":"3","author":"Whittaker","year":"2013","journal-title":"Cancer Discov"},{"key":"key20200713185040_b15-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.celrep.2013.08.023","article-title":"Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma","volume":"4","author":"Villanueva","year":"2013","journal-title":"Cell Reports"},{"key":"key20200713185040_b16-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1158\/2159-8290.CD-13-0631","article-title":"MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF\/MEK inhibition","volume":"4","author":"Wagle","year":"2014","journal-title":"Cancer Discov"},{"key":"key20200713185040_b17-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","article-title":"Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy","volume":"4","author":"Shi","year":"2014","journal-title":"Cancer Discov"},{"key":"key20200713185040_b18-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1470-2045(13)70024-X","article-title":"MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: A non-randomised, open-label phase 2 study","volume":"14","author":"Ascierto","year":"2013","journal-title":"Lancet Oncol"},{"key":"key20200713185040_b19-ijo-53-03-1149","first-page":"1631","article-title":"Profile of selumetinib and its potential in the treatment of melanoma","volume":"7","author":"Kim","year":"2014","journal-title":"Onco Targets Ther"},{"key":"key20200713185040_b20-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.2217\/fon.14.89","article-title":"Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma","volume":"10","author":"King","year":"2014","journal-title":"Future Oncol"},{"key":"key20200713185040_b21-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1200\/JCO.2015.62.9345","article-title":"Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib","volume":"34","author":"Long","year":"2016","journal-title":"J Clin Oncol"},{"key":"key20200713185040_b22-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): Updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"key":"key20200713185040_b23-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1158\/2159-8290.CD-13-0617","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov"},{"key":"key20200713185040_b24-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ejca.2016.04.005","article-title":"Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next","volume":"62","author":"Welsh","year":"2016","journal-title":"Eur J Cancer"},{"key":"key20200713185040_b25-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.2741\/2909","article-title":"The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases","volume":"13","author":"Hassa","year":"2008","journal-title":"Front Biosci"},{"key":"key20200713185040_b26-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nrc2812","article-title":"PARP inhibition: PARP1 and beyond","volume":"10","author":"Rouleau","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"key20200713185040_b27-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"23028","DOI":"10.1074\/jbc.M202390200","article-title":"Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1","volume":"277","author":"Schreiber","year":"2002","journal-title":"J Biol Chem"},{"key":"key20200713185040_b28-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0027-5107(00)00039-7","article-title":"Base excision repair in yeast and mammals","volume":"451","author":"Memisoglu","year":"2000","journal-title":"Mutat Res"},{"key":"key20200713185040_b29-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/1541-7786.MCR-13-0672","article-title":"Transcriptional roles of PARP1 in cancer","volume":"12","author":"Schiewer","year":"2014","journal-title":"Mol Cancer Res"},{"key":"key20200713185040_b30-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.ejca.2008.03.019","article-title":"Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity","volume":"44","author":"Tentori","year":"2008","journal-title":"Eur J Cancer"},{"key":"key20200713185040_b31-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1158\/1078-0432.CCR-06-3039","article-title":"ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models","volume":"13","author":"Donawho","year":"2007","journal-title":"Clin Cancer Res"},{"key":"key20200713185040_b32-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1111\/cas.13307","article-title":"Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors","volume":"108","author":"Nishikawa","year":"2017","journal-title":"Cancer Sci"},{"key":"key20200713185040_b33-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1093\/annonc\/mdv308","article-title":"Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma","volume":"26","author":"Middleton","year":"2015","journal-title":"Ann Oncol"},{"key":"key20200713185040_b34-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"7277","DOI":"10.1158\/1078-0432.CCR-09-1245","article-title":"ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors","volume":"15","author":"Palma","year":"2009","journal-title":"Clin Cancer Res"},{"key":"key20200713185040_b35-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/00008390-200508000-00002","article-title":"Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases","volume":"15","author":"Carta","year":"2005","journal-title":"Melanoma Res"},{"key":"key20200713185040_b36-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"26562","DOI":"10.1074\/jbc.M115.676130","article-title":"Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy","volume":"290","author":"Chang","year":"2015","journal-title":"J Biol Chem"},{"key":"key20200713185040_b37-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1038\/s41598-017-01425-9","article-title":"Retro-inverso urokinase receptor antagonists for the treatment of metastatic sarcomas","volume":"7","author":"Carriero","year":"2017","journal-title":"Sci Rep"},{"key":"key20200713185040_b38-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13046-017-0650-x","article-title":"Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells","volume":"36","author":"Ragone","year":"2017","journal-title":"J Exp Clin Cancer Res"},{"key":"key20200713185040_b39-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/1479-5876-10-85","article-title":"The role of BRAF V600 mutation in melanoma","volume":"10","author":"Ascierto","year":"2012","journal-title":"J Transl Med"},{"key":"key20200713185040_b40-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12974-016-0729-x","article-title":"PARP inhibition in leukocytes diminishes inflammation via effects on integrins\/cytoskeleton and protects the blood-brain barrier","volume":"13","author":"Rom","year":"2016","journal-title":"J Neuroinflammation"},{"key":"key20200713185040_b41-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"e1003531","DOI":"10.1371\/journal.pgen.1003531","article-title":"PARP-1 regulates metastatic melanoma through modulation of vimentin-induced malignant transformation","volume":"9","author":"Rodr\u00edguez","year":"2013","journal-title":"PLoS Genet"},{"key":"key20200713185040_b42-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1186\/s12967-015-0736-1","article-title":"Future perspectives in melanoma research: meeting report from the 'Melanoma Bridge': Napoli, December 3rd-6th 2014","volume":"13","author":"Ascierto","year":"2015","journal-title":"J Transl Med"},{"key":"key20200713185040_b43-ijo-53-03-1149","first-page":"1071","article-title":"Cutaneous melanoma: From pathogenesis to therapy (Review)","volume":"52","author":"Leonardi","year":"2018","journal-title":"Int J Oncol"},{"key":"key20200713185040_b44-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.humpath.2005.04.017","article-title":"Poly(adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region","volume":"36","author":"Staibano","year":"2005","journal-title":"Hum Pathol"},{"key":"key20200713185040_b45-ijo-53-03-1149","first-page":"5370","article-title":"Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma","volume":"9","author":"Tentori","year":"2003","journal-title":"Clin Cancer Res"},{"key":"key20200713185040_b46-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1158\/1078-0432.CCR-16-1040","article-title":"PARP inhibitor activity correlates with SLFN11 expression and demonstrates synergy with temozolomide in small cell lung cancer","volume":"23","author":"Lok","year":"2017","journal-title":"Clin Cancer Res"},{"key":"key20200713185040_b47-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.2147\/OTT.S139336","article-title":"Current status of poly(ADP-ribose) polymerase inhibitors and future directions","volume":"10","author":"Ohmoto","year":"2017","journal-title":"OncoTargets Ther"},{"key":"key20200713185040_b48-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.2147\/OTT.S69935","article-title":"Profile of veliparib and its potential in the treatment of solid tumors","volume":"8","author":"Wagner","year":"2015","journal-title":"OncoTargets Ther"},{"key":"key20200713185040_b49-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nrclinonc.2014.163","article-title":"An update on PARP inhibitors - moving to the adjuvant setting","volume":"12","author":"Sonnenblick","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"key20200713185040_b50-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/ijc.29531","article-title":"Expression of nuclear matrix proteins binding matrix attachment regions in prostate cancer. PARP-1: New player in tumor progression","volume":"137","author":"Barboro","year":"2015","journal-title":"Int J Cancer"},{"key":"key20200713185040_b51-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1038\/bjc.2012.395","article-title":"Erythropoietin-driven signalling and cell migration mediated by polyADP-ribosylation","volume":"107","author":"Inbar","year":"2012","journal-title":"Br J Cancer"},{"key":"key20200713185040_b52-ijo-53-03-1149","doi-asserted-by":"publisher","first-page":"240","DOI":"10.7150\/jca.16402","article-title":"Benzyl-isothiocyanate induces apoptosis and inhibits migration and invasion of hepatocellular carcinoma cells in vitro","volume":"8","author":"Zhu","year":"2017","journal-title":"J Cancer"},{"key":"key20200713185040_b53-ijo-53-03-1149","first-page":"415","article-title":"Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors","volume":"26","author":"Tentori","year":"2005","journal-title":"Int J Oncol"}],"container-title":["International Journal of Oncology"],"original-title":[],"deposited":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T18:58:58Z","timestamp":1594666738000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ijo.2018.4457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,27]]},"references-count":53,"URL":"https:\/\/doi.org\/10.3892\/ijo.2018.4457","relation":{},"ISSN":["1019-6439","1791-2423"],"issn-type":[{"value":"1019-6439","type":"print"},{"value":"1791-2423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,27]]}}}